Payment overview · 2025
General Payments
$224.40
11 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Ben Burgett, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · AUXIER, KY · NPI 1598865677
Verified facts
What the public records show
CMS Open Payments records show Robert Ben Burgett, D.O. received $224.40 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.48 | 41.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.54 | 15.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.08 | 10.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.03 | 9.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.86 | 8.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.35 | 8.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.06 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.40 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $53.44 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.54 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 413 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 69 |
| Lisinopril | Lisinopril | 318 | 64 |
| Omeprazole | Omeprazole | 284 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 46 |
| Metformin Hcl | Metformin Hcl | 207 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 195 | 48 |
| Gabapentin | Gabapentin | 190 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 43 |
| Furosemide | Furosemide | 169 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 36 |
| Losartan Potassium | Losartan Potassium | 155 | 34 |
| Diazepam | Diazepam | 140 | 24 |
| Sertraline Hcl | Sertraline Hcl | 134 | 27 |
| Trazodone Hcl | Trazodone Hcl | 128 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 23 |
| Allopurinol | Allopurinol | 106 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 29 |
| Montelukast Sodium | Montelukast Sodium | 97 | 18 |
| Simvastatin | Simvastatin | 96 | 24 |
| Ozempic | Semaglutide | 95 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 21 |
| Prednisone | Prednisone | 86 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 27 |
| Carvedilol | Carvedilol | 79 | 17 |
| Glipizide | Glipizide | 78 | 12 |
| Potassium Chloride | Potassium Chloride | 78 | 19 |
| Mounjaro | Tirzepatide | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 15 |
| Farxiga | Dapagliflozin Propanediol | 71 | 19 |
| Buspirone Hcl | Buspirone Hcl | 68 | suppressed |
| Azithromycin | Azithromycin | 62 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Metformin Hcl Er | Metformin Hcl | 56 | 15 |
| Sucralfate | Sucralfate | 55 | 12 |
| Theophylline Er | Theophylline Anhydrous | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Linzess | Linaclotide | 54 | 16 |
| Eliquis | Apixaban | 53 | 11 |
| Famotidine | Famotidine | 52 | 14 |
| Jardiance | Empagliflozin | 52 | suppressed |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | suppressed |
| Lorazepam | Lorazepam | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Atenolol | Atenolol | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Finasteride | Finasteride | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.40 · 11 records | ABBVIE INC. | CAPLYTA, Cologuard Collection Kit, FANAPT, GEMTESA, HETLIOZ, NUZYRA, QULIPTA, UBRELVY, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error